• International Society of Paediatric Oncology Europe Neuroblastoma

Nuclear Medicine and Physics Committee


The Nuclear Medicine and Physics Committee’s aims are to set standards for acquiring and reporting diagnostic paediatric MIBG scans across Europe, and to develop a virtual platform for remote image review supporting clinical management, audit and research.

A team of nuclear medicine specialists representing 17 countries have undergone a training program to standardize techniques for acquiring diagnostic MIBG data and implement a semi quantitative reporting system for paediatric MIBG scans. A system for remote image viewing and reporting has been established allowing diagnostic MIBG scans for children entered into the high risk treatment protocol to be reviewed using this system.

The Committee’s main objective is to achieve consistency in paediatric MIBG image reporting by expanding the number of nuclear medicine specialists trained to use the agreed semi quantitative scoring system.

The immediate priority is to continue to review and report nuclear medicine imaging data for all patients recruited to the high dose neuroblastoma protocol.

The future plans are:

  • To manage predicted workload and support future research, the number of nuclear medicine specialists trained to use the remote image reviewing system must be expanded. It is anticipate that training will be delivered ‘on-line’ by existing national representatives supported by an educational reference atlas and mentored review.
  • To promote and maintain the quality of diagnostic MIBG scintigraphies performed in all children investigated for neuroblastoma. Data collection and online scoring and reporting are mandatory with respect to that issue. Tremendous efforts have been made by the committee members, and especially by the previous chairpersons (Val Lewington and Glenn Flux).

A semi-quantitative scoring system has been developed under the leadership of Val Lewington. It was used to analyze the pre and post-therapeutic data obtained in children included in the High-Risk study, but also the pre- and post-immunotherapy scintigraphies. Collaborative work with the Children’s Oncology Group aiming at defining the best method to read and score the scans began in 2012 and is ongoing.

SIOPEN meetings

Forthcoming meetings:

Berlin (Germany) AGM

25-27 October 2017 

click for more information


SIOPEN Verein zur Foderung der Neuroblastomforschung is an Association registered in Austria and recognised as a non-profit organisation according to the Austrian Federal Tax Code (Bundesabgabenordnung BAO). Registration number ZVR 396592912. The SIOPEN Association was officially established on 20 January 2009.

This website makes use of stock photography and images do not represent particular individuals treated by SIOPEN institutions.